关于天然产品对抗肌缩侧面硬化症 (ALS) 的见解
Kadja Luana Chagas Monteiro1, Marcone Gomes Dos Santos Alcântara1, Thiago Mendonça de Aquino1
1Research Group on Therapeutic Strategies - GPET, Laboratory of Synthesis and Research in Medicinal Chemistry - LSPMED, Institute of Chemistry and Biotechnology, Federal University of Alagoas, 57072-970, Maceió, Alagoas, Brazil.
药用草药在治疗肌缩侧面硬化症 (ALS),一种运动神经元疾病方面表现有前途. 它们穿越血脑屏障的能力和低毒性使它们成为有价值的补充疗法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 草药是一种草药.
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种进展性神经退行性疾病,其特征是运动神经元死亡和肌肉.
- 目前对ALS的治疗选择有限,这引发了对补充和替代医学的兴趣.
- 药用植物正在研究它们在ALS中的潜在神经保护作用.
研究的目的:
- 审查药用草药对肌缩侧面硬化症 (ALS) 的治疗潜力.
- 探索草药化合物与ALS生理病理路径之间的关系.
- 为了突出血脑屏障透特性和低毒性用于ALS治疗的草药.
主要方法:
- 关于药用草药和ALS研究的文献综述.
- 对与ALS相关的草药制剂作用机制的分析.
- 评估研究中的草药的毒性和血脑屏障的透.
主要成果:
- 几种药用草本在ALS的临床前和临床研究中显示出潜在的潜力.
- 已识别的草药向关键的ALS途径,包括氧化应激和兴奋毒性.
- 具有有利的药理学特征 (例如,BBB透) 的草药化合物被突出显示.
结论:
- 药用草药是ALS治疗中补充疗法的有希望的途径.
- 对特定草药化合物的进一步研究可能会导致新的ALS治疗方法.
- 某些草药的低毒性和BBB透率要求对ALS进行临床研究.
更多相关视频
10:49Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
Published on: September 18, 2011
12:35Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
Published on: March 17, 2012
相关概念视频
Parkinson's Disease: Overview
Alzheimer's Disease: Treatment
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
